Arthex Biotech
VerifiedFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. Learn more
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$185—277m (Dealroom.co estimates May 2023.)
Company register number B40613259
Paterna Valencian Community (HQ)
- hard tech
- biotechnology
- horizon europe
- woman founder
- biotech and pharma
- spinout
- eit ecosystem
- genetics
- eit health
- drug development
- techbio
- eit supernovas
- ai drug discovery
- eicfund
- research and development
- digital pharma
- techbio drug discovery
- headstart (eit health)
- genomics
- headstart 2020 (eit health)
- rna
- caixa impulse (eit health)
- caixa impulse 2017 (eit health)
| EUR | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 686 % | 50 % |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | (1444 %) | (590 %) | (1159 %) |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | (1444 %) | (616 %) | (1561 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | $0.0 | round |
| investor investor investor | $0.0 | round | |
| investor investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
* | €42.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Recent News about Arthex Biotech
EditMore about Arthex Biotech
EditDeveloper of anti-microRNAs designed for the treatment of diseases with unmet needs. The company develops drugs and therapies that are designed to treat a variety of disorders in which microRNAs play a role, enabling medical professionals to get access to therapy that helps treat patients suffering from genetic diseases, rare diseases, and diseases with high medical needs.
Keywords: Pharmaceuticals and Biotechnology, Antisense Oligonucleotide, Antisense Oligonucleotide Therapy, Muscular Dystrophy, Neuromuscular Disease, Neuromuscular Disease Therapeutics, Neuromuscular Disease Treatment, Neuromuscular Therapy, Oligonucleotide Therapeutics, Oligonucleotide Therapy.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.